Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2023-12-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于公司财务总监辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's financial director, including details about the resignation date, interim arrangements, and shareholding status of the resigning officer. It does not contain financial statements, audit information, or detailed financial results. It is a management change announcement related to senior management personnel. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming this classification.
2023-12-11 Chinese
第六届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's sixth board of directors meeting held on October 25, 2023. It includes approval of the company's 2023 third quarter report and a decision to sell a subsidiary. The document is short (1025 characters) and primarily announces board meeting decisions rather than providing detailed financial statements or full reports. It also references where the full third quarter report can be found, indicating this document is not the report itself. The content fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and management decisions.
2023-10-26 Chinese
独立董事关于第六届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting agenda item regarding the sale of a subsidiary. It references compliance with company law and internal regulations, and provides an independent judgment on the transaction's fairness and alignment with shareholder interests. This type of document is related to board or management information, specifically about a corporate transaction decision. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or announcement of a report. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management/board opinion rather than financial data or regulatory compliance filings.
2023-10-26 Chinese
第六届监事会第八次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the approval of the company's 2023 third quarter report and a transaction involving the sale of a subsidiary. It includes voting results and confirms the meeting was held in compliance with relevant laws. The document does not contain the actual third quarter financial report but refers readers to the full report on an external website. The document is short (1091 characters) and serves as an official announcement of meeting resolutions and voting outcomes rather than the report itself. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-10-26 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '康芝药业股份有限公司2023 年第三季度报告' which translates to 'Kangzhi Pharmaceutical Co., Ltd. 2023 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and financial metrics for the third quarter of 2023. The document explicitly states it is a quarterly report and mentions it is unaudited. The length is over 11,000 characters, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial statements and management discussion of financial results for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-10-26 Chinese
2023年第三季度报告提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (473 characters) indicating that the company's 2023 third quarter report has been approved and is available on the official disclosure website. It does not contain the actual financial data or the full report itself, but rather directs investors to where the full report can be found. According to the 'MENU VS MEAL' rule, such a brief notice announcing the availability of a report is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2023-10-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.